Safety of COVID-19 vaccines and disease flares after vaccines in children with rheumatic disease

References

• Organization WH Director-general’s opening remarks at the media briefing on COVID-19–11 March 2020. https://wwwwhoint/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19—11-march-2020.
   Google Scholar
• Orginaziton WH https://covid19.who.int 2022 [2022 Mar 3].
   Google Scholar
• Anand U, Jakhmola S, Indari O, et al. Potential therapeutic targets and vaccine development for SARS-CoV-2/COVID-19 pandemic management: a review on the recent update. Front Immunol. 2021;12:658519.
   PubMed Web of Science ®Google Scholar
• Cui X, Zhao Z, Zhang T, et al. A systematic review and meta‐analysis of children with coronavirus disease 2019 (COVID‐19). J Med Virol. 2021;93:1057–1069.
   PubMed Web of Science ®Google Scholar
• Cura Yayla BC, Özsürekçi Y, Aykaç K, et al. Characteristics and management of children with COVID-19 in Turkey. Balkan Med J. 2020;37:341–347.
   PubMed Web of Science ®Google Scholar
• Ozsurekci Y, Gürlevik S, Kesici S, et al. Multisystem inflammatory syndrome in children during the COVID-19 pandemic in Turkey: first report from the Eastern Mediterranean. Clin Rheumatol. 2021;40:3227–3237. Epub 2021 Feb 12. Erratum in: Clin Rheumatol. 2021 Mar 19.
   PubMed Web of Science ®Google Scholar
• Aydin O, Kaynak MO, Sabuncuoglu S, et al. The effects of COVID-19 on oxidative stress and antioxidant defense mechanism in children. J Pediatr Infect Dis. 2022;17(2):112–118.
   Web of Science ®Google Scholar
• Bunyavanich S, Do A, Vicencio A. Nasal gene expression of angiotensin-converting enzyme 2 in children and adults. JAMA. 2020;323:2427–2429.
   PubMed Web of Science ®Google Scholar
• Cristiani L, Mancino E, Matera L, et al. Will children reveal their secret? The coronavirus dilemma. Eur Respir J. 2020;55:2000749.
   PubMed Web of Science ®Google Scholar
• Prevention CfDCa. Emergency preparedness and response: HAN00432. [cited 2022 Mar 3]. Available from: https://emergency.cdc.gov/han/2020/han00432.asp.
   Google Scholar
• Shekerdemian LS, Mahmood NR, Wolfe KK, et al. Characteristics and outcomes of children with coronavirus disease 2019 (COVID-19) infection admitted to US and Canadian pediatric intensive care units. JAMA Pediatr. 2020;174(9):868–873.
   PubMed Web of Science ®Google Scholar
• Dufort EM, Koumans EH, Chow EJ, et al. Multisystem inflammatory syndrome in children in New York State. N Engl J Med. 2020;383:347–358.
   PubMed Web of Science ®Google Scholar
• Feldstein LR, Rose EB, Horwitz SM, et al. Multisystem inflammatory syndrome in US children and adolescents. N Engl J Med. 2020;383:334–346.
   PubMed Web of Science ®Google Scholar
• Ludvigsson JF. Case report and systematic review suggest that children may experience similar long‐term effects to adults after clinical COVID‐19. Acta Paediatrica. 2021;110:914–921.
   PubMed Web of Science ®Google Scholar
• Buonsenso D, Munblit D, De Rose C, et al. Preliminary evidence on long COVID in children. Acta Paediatr. 2021;110:2208–2211.
   PubMed Web of Science ®Google Scholar
• Laçinel Gürlevik S, Günbey C, Ozsurekci Y, et al. Neurologic manifestations in children with COVID-19 from a tertiary center in Turkey and literature review. Eur J Paediatr Neurol. 2022;37:139–154. Epub 2022 Feb 18.
   PubMed Web of Science ®Google Scholar
• Kihira S, Morgenstern PF, Raynes H, et al. Fatal cerebral infarct in a child with COVID-19. Pediatr Radiol. 2020 2020 Jul 23;50:1479–1480. Epub.
   PubMed Web of Science ®Google Scholar
• Frank CHM, Almeida TVR, Marques EA, et al. Guillain-Barré syndrome associated with SARS-CoV-2 infection in a pediatric patient. J Trop Pediatr. 2021;67:fmaa044.
   PubMed Web of Science ®Google Scholar
• McAbee GN, Brosgol Y, Pavlakis S, et al. Encephalitis Associated with COVID-19 Infection in an 11-Year-Old Child. Pediatr Neurol. 2020 Epub 2020 Apr 24;109:94.
   PubMed Web of Science ®Google Scholar
• TURCOVID19. Türkiye COVID19 Aşılama Grupları Aşı Uygulama Tarihleri 2021. [cited 2022 Mar 3]. Available from: https://turcovid19.com/etkinlikler/turkiye-covid19-asilama-gruplari-asi-uygulama-tarihleri/.
   Google Scholar
• Sharma O, Sultan AA, Ding H, et al. A review of the progress and challenges of developing a vaccine for COVID-19. Front Immunol. 2020;11:585354.
   PubMed Web of Science ®Google Scholar
• Frenck RW Jr., Klein NP, Kitchin N, et al. Safety, Immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. N Engl J Med. 2021;385:239–250.
   PubMed Web of Science ®Google Scholar
• Xia S, Zhang Y, Wang Y, et al. Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial. Lancet Infect Dis. 2021;S1473-3099(21):00462–X.
   Google Scholar
• Lv M, Luo X, Shen Q, et al. Safety, Immunogenicity, and Efficacy of COVID-19 vaccines in children and adolescents: a systematic review. Vaccines (Basel). 2021;9:1102.
   PubMed Web of Science ®Google Scholar
• Curtis JR, Johnson SR, Anthony DD, et al. American college of rheumatology guidance for COVID‐19 vaccination in patients with rheumatic and musculoskeletal diseases: Version 3. Arthritis Rheumatol. 2021;73:e60–e75.
   PubMed Web of Science ®Google Scholar
• PReS. PRES update regarding COVID-19 vaccination in children with rheumatic diseases 2021 [21 Sept 2020]. Available from: https://www.pres.eu/clinical-affairs/guidelines.html.
   Google Scholar
• Sattui SE, Liew JW, Kennedy K, et al. Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 global rheumatology alliance vaccine survey. RMD Open. 2021;7:e001814.
   PubMed Web of Science ®Google Scholar
• Orginaziton WH Side effects of COVID-19 vaccines 2021 [cited 2021 9 Dec 2021 Dec 9]. Available from: https://www.who.int/news-room/feature-stories/detail/side-effects-of-covid-19-vaccines.
   Google Scholar
• Yurttas B, Poyraz BC, Sut N, et al. Willingness to get the COVID-19 vaccine among patients with rheumatic diseases, healthcare workers and general population in Turkey: a web-based survey. Rheumatol Int. 2021;41:1105–1114.
   PubMed Web of Science ®Google Scholar
• Akgün Ö, Kayaalp GK, Demirkan FG, et al. Exploring the attitudes, concerns, and knowledge regarding COVID-19 vaccine by the parents of children with rheumatic disease: Cross-sectional online survey. Vaccine. 2022;40:1829–1836.
   PubMed Web of Science ®Google Scholar
• Monti S, Balduzzi S, Delvino P, et al. Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. Ann Rheum Dis. 2020;79:667–668.
   PubMed Web of Science ®Google Scholar
• Pablos JL, Abasolo L, Alvaro-Gracia JM, et al. Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases. Ann Rheum Dis. 2020;79:1170–1173.
   PubMed Web of Science ®Google Scholar
• Sozeri B, Ulu K, Kaya-Akça U, et al. The clinical course of SARS-CoV-2 infection among children with rheumatic disease under biologic therapy: a retrospective and multicenter study. Rheumatol Int. 2022;42(3):469–475.
   PubMed Web of Science ®Google Scholar
• Conway R, Grimshaw AA, Konig MF, et al. COVID-19 global rheumatology alliance. SARS-CoV-2 Infection and COVID-19 outcomes in rheumatic diseases: A systematic literature review and meta-analysis. Arthritis Rheumatol. 2021 Nov 22. DOI:10.1002/art.42030. Epub ahead of print.
   Web of Science ®Google Scholar
• Santosa A, Xu C, Arkachaisri T, et al. Recommendations for COVID-19 vaccination in people with rheumatic disease: Developed by the Singapore chapter of rheumatologists. Int J Rheum Dis. 2021;24:746–757.
   PubMed Web of Science ®Google Scholar
• Nyberg T, Ferguson NM, Nash SG, et al. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron.
   Google Scholar
• Pérez-Then E, Lucas C, Monteiro VS, et al. Neutralizing antibodies against the SARS-CoV-2 delta and omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination. Nat Med. 2022;28:481–485. Epub 2022 Jan 20.
   PubMed Web of Science ®Google Scholar
• Furer V, Rondaan C, Agmon-Levin N, et al. Point of view on the vaccination against COVID-19 in patients with autoimmune inflammatory rheumatic diseases. RMD Open. 2021;7:e001594.
   PubMed Web of Science ®Google Scholar
• Hause AM, Gee J, Baggs J, et al. COVID-19 vaccine safety in adolescents aged 12–17 Years—United States. MMWR Morb Mortal Wkly Rep. 2020;70:1053–1058. 2021 Dec 14, –Jul 14, –Jul 16.
   Web of Science ®Google Scholar
• Revon-Riviere G, Ninove L, Min V, et al. The BNT162b2 mRNA COVID-19 vaccine in adolescents and young adults with cancer: a monocentric experience. Eur J Cancer. 2021;154:30–34.
   PubMed Web of Science ®Google Scholar
• Rotondo C, Cantatore FP, Fornaro M, et al. Preliminary data on post market safety profiles of COVID 19 vaccines in rheumatic diseases: Assessments on various vaccines in use, different rheumatic disease subtypes, and immunosuppressive therapies: A two-centers study. Vaccines (Basel). 2021;9:730.
   PubMed Web of Science ®Google Scholar
• Yeo JG, Chia WN, Teh KL, et al. Robust neutralising antibody response to SARS-CoV-2 mRNA vaccination in adolescents and young adults with childhood onset rheumatic diseases. Rheumatology (Oxford). 2022; keac105. Epub ahead of print. 10.1093/rheumatology/keac105
   PubMed Web of Science ®Google Scholar
• Haslak F, Gunalp A, Cebi MN, et al. Early experience of COVID-19 vaccine-related adverse events among adolescents and young adults with rheumatic diseases: a single-center study. Int J Rheum Dis. Epub. 2022 Jan 3; 2022;253:353–363.
   PubMed Web of Science ®Google Scholar
• Braun-Moscovici Y, Kaplan M, Braun M, et al. Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2. Ann Rheum Dis. 2021;80:1317–1321.
   PubMed Web of Science ®Google Scholar